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Nanocarriers targeting senescent cells
a b s t r a c t
Ageing and multiple chronic diseases in humans associate with an aberrant accumulation of senescent
cells in a diversity of tissues, which contributes to organ dysfunction and drives their pathological
manifestations. It emerges that elimination of senescent cells ameliorates and even reverts the pro-
gression of age-related disorders, thereby extending healthspan and lifespan in preclinical mouse
models. Development of delivery carriers speciﬁcally targeting senescent cells offers innovative thera-
peutic and diagnostic applications in translational medicine.
© 2019 KeAi Communications Co., Ltd. Publishing Services by Elsevier B.V. on behalf of KeAi Commu-
nications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1. Introduction
Severe or unrepairable damage often elicits across vertebrates a
cell autonomous response based on a stable cell cycle arrest, known
as cellular senescence. This cellular fate involves the upregulation
of survival pathways and the acquisition of a senescence-
associated secretory phenotype (SASP) that entails a complex
mixture of cytokines, proteases and other extracellular matrix
remodelling factors. The main role of cellular senescence is to pre-
vent the expansion of damaged cells and to facilitate tissue repair.
Senescent cells during ageing, however, accumulate in multiple tis-
sues, probably due to inefﬁcient clearance by immune cells, where
they contribute to disease onset and progression through a series of
complex cell autonomous and proinﬂammatory! tissue disrup-
tive! paracrine effects that impact both the surrounding microen-
vironment and tissue homeostasis. Cellular senescence thus relates
to a wide variety of human age-related pathologies including,
among others, cancer, ﬁbrosis, cardiovascular diseases, obesity,
type 2 diabetes, sarcopenia, osteoarthritis, and neurological disor-
ders [1]. Importantly, genetic ablation of senescent (p16Ink4a-posi-
tive) cells in mice attenuates tissue dysfunction and symptoms of
frailty, leading to an increased healthspan and lifespan [2].
Senescent cells possess distinct molecular vulnerabilities target-
able by senolytic drugs (pharmacologically active agents that selec-
tively kill senescent cells) [3,4]. Research over the last few years has
produced preclinical proof-of-concept that senotherapies do delay,
prevent, or revert multiple age-related phenotypes, chronic disor-
ders, geriatric syndromes and loss of physiological resilience [4,5],
while lengthening life in old age mice [6]. Because of the unfortu-
nate presence of undesirable off-target effects is a common feature
of these pharmacological interventions that hampers a more effec-
tive translation of preclinical studies into early phase clinical trials,
many different strategies for optimising selectivity of senolytic
drugs are currently under evaluation.
Over the past decades, nanomedicine has been a research area
in continuous expansion aimed at impacting broadly on healthcare
[7]. The application of gated materials in the biomedical ﬁeld has
been boosted because these systems allow the release of one or
several cargoes upon the application of external stimuli [8]. Func-
tionalised nanoparticles (NPs) with amolecular gate are able to efﬁ-
ciently carry and speciﬁcally deliver therapeutic agents, imaging
probes, or biological materials to targeted sites such as a particular
organ, tissue, or even cellular type (Fig. 1A). The ﬁrst cargo
delivery system reported to target senescent cells consisted of mes-
oporous silica nanoparticles capped with a mixture of galacto-
oligosaccharides (GosNPs) of different lengths [9] (Fig. 1B). Cellular
uptake of GosNPs occurs via endocytosis and, after fusionwith lyso-
somal vesicles, the cargo is preferentially released in cells with
increased endogenous senescence-associated b-galactosidase (SAb
gal) activity, a widely used marker of senescence, which mediates
enzymatic hydrolysis of the cap. By using this approach, the authors
showed the preferential release of rhodamine in human senescent
ﬁbroblasts from dyskeratosis congenita patients.
1.1. Therapeutic nanoparticles
We have improved the former technology by generating silica
beads capped with a homogeneous coating consisting mostly of 6-
mer galacto-oligosaccharides (GalNPs) (Fig. 1B), which allows for a
more speciﬁc and controlled b-galactosidase-dependent cargo
release when compared to GosNPs. GalNPs were validated in
in vivo models of damage-induced and chemotherapy-induced
senescence [10]. We demonstrated that gal-encapsulated drugs
are preferentially released into damaged or pathological tissues con-
taining high levels of senescent cells, such as bleomycin-induced
lung ﬁbrosis. Importantly, the release of gal-encapsulated doxoru-
bicin into ﬁbrotic lungs does revert pulmonary ﬁbrosis, in stark
contrast to the administration of free doxorubicin, as it results in a
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remarkable reduction in the abnormal amount of collagen present
and in the recovery of respiratory function. Furthermore, chemo-
therapy treatment of xenograft tumours in mice causes a fraction
of tumour cells to undergo senescence, and the concomitant treat-
ment with gal-encapsulated doxorubicin results in full tumour
regression. Of note, we found that gal-encapsulation prevents the
exposure of non-pathological tissues to drugs, therefore reducing
their associated toxicities. Our work obtained for the ﬁrst-time proof
of principle for the in vivo biological activity of a vehicle that allows
preferential drug delivery into diseased tissues harbouring senes-
cent cells. This may open new therapeutic opportunities for the
treatment of multiple senescence-associated disorders and, addi-
tionally, targeted-delivery of drugs into senescent cellsmay improve
cancer chemotherapy by eliminating tumour cells undergoing
chemotherapy-induced senescence (Fig. 2).
Besides their capability to kill senescent cells, nanocarriers
remarkably also have the attractive potential to dampen the detri-
mental effects of cellular senescence by manipulating the SASP
with encapsulated inhibitors, effectors and small molecules, or by
reprogramming these cells so they can accomplish their tissue-
associated functions. A recent in vitro study makes use of porous
calcium carbonate nanoparticles (CaCO3) loaded with rapamycin
(Rapa, an mTOR inhibitor capable of constraining the secretory
phenotype of senescent cells) [11] (Fig. 1B). CaCO3(Rapa) NPs
were wrapped with a conjugate of lactose (Lac, galactose/glucose
dimers joined in a b-1,4- glycosidic linkage) for a targeted cargo
release mediated by SAbgal activity; and with polyethylene glycol,
for a conceivable stabilisation in circulating blood and prevention
of opsonisation. These NPs were further functionalised with a
monoclonal antibody against CD9, a cell surface glycoprotein recep-
tor overexpressed in some cellular types undergoing senescence.
CD9-Lac/CaCO3 NPs were thus designed as a targeted delivery sys-
tem at two levels: (i) by using surface targetable proteins of senes-
cent cells leading to cell speciﬁc uptake, (ii) by exploiting an
increased lysosomal enzymatic activity of senescent cells for a
preferential cargo release. The authors showed that CD9-Lac/
CaCO3(Rapa) exhibited anti-senescence effects in primary human
dermal ﬁbroblasts (HDFs), along with a reduced expression of
some SASP components, including IL-6 and IL-1b. In another recent
study, molybdenum disulphide nanoparticles (MoS2 NPs, see
Fig. 1B) pre-treatment of human aortic endothelial cells succeeded
to inhibit H2O2-induced senescence by preventing lysosomal and
mitochondrial dysfunction, triggering autophagy and resisting
impaired autophagic ﬂux, which results in improved endothelial
functions [12]. However, MoS2 nanodevices, differently to GalNPs
or CD9-Lac/CaCO3 NPs, were not functionalised for a preferential
targeting of senescent cells, thereby limiting their current in vivo
potential applications to in situ preventive treatments for damaged
tissues. Despite the aforementioned promising ﬁndings, the in vivo
efﬁciency of most of these emerging nanovehicles still lack
Fig. 1. Therapeutic and diagnostic applications of nanoparticles targeting senescent cells. (A) Nanocarriers can be loaded with multiple cargoes, either for therapeutic or diagnostic
applications, as indicated. Nanocarriers can in addition be functionalised with polymers, ligands or antibodies for a selective targeting of senescent cells. SASP, senescence-
associated secretory phenotype. MRI, magnetic resonance imaging. PET, positron emission tomography. SPECT, single-photon emission computed tomography. Tx, therapy. (B)
Different nanodevices to target senescent cells according to their physicochemical properties. GosNPs and GalNPs, galacto-oligosaccharide coated mesoporous silica nanoparticles;
CD9-Lac/CaCO3 NPs, CD9 monoclonal antibody-conjugated calcium carbonate nanoparticles wrapped with lactose-polyethylene glycol; MoS2 NPs, molybdenum disulphide
nanoparticles.
Fig. 2. Rationale of the applications of seno-nanotherapies. Nanotherapies can be used
to remove the senescent burden associated with chronic disorders or during ageing,
thereby promoting tissue repair and regeneration. Also, an interesting application is
the combined use of nanotherapies and senescence-inducing chemotherapies or ra-
diotherapies in so to facilitate tumour regression and the eradication of senescent cells.
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demonstration in preclinical models.
1.2. Diagnostic nanoparticles
In addition to therapeutic approaches, monitoring senescent le-
sions in humans remains a formidable challenge in clinical imaging.
To date, the list of imaging probes reported to track senescent cells
is a short one, these probes are based mainly on ﬂuorescent mole-
cules, only tested in cell cultures in most of the cases. This includes
two-photon SG1 [13] and single photon near-infrared Gal-Pro [14]
probes assessed in senescent HDFs, and AHGa, a naphthalimide-
based probe conjugated with acetylated galactose tested in SK-
MEL103 (melanoma) xenografts undergoing chemotherapy-
induced senescence [15]. These senoprobes are preferentially acti-
vated in cells exhibiting high SAbgal activity and contain ﬂuores-
cent units conjugated with a galactose residue via a glycosidic
bond. Crucially, the conceivable use of current ﬂuorescent probes
to detect senescent lesions in humans would require their adapta-
tion to deep tissue penetration bioimaging techniques.
Nanocarriers speciﬁcally targeting senescent cells represent an
elegant translational option as they can encapsulate tracers,
contrast agents, radionuclides, and even senoprobes (Fig. 1A). As
an example, diagnostic GalNPs, capable of releasing ﬂuorescent
dyes in senescent tumour xenografts [10], could be loaded with
gadolinium or with radioactive tracers to track senescent tissues
by magnetic resonance imaging (MRI) or positron emission to-
mography (PET), respectively. It is tempting to speculate that diag-
nostic nanocarriers could hence be employed in longitudinal
studies to monitor the senescent burden in patients subjected to
senotherapies, or the response of solid tumours to the administra-
tion of senescence-inducing chemotherapies. Moreover, since
cellular senescence is a hallmark of numerous human precancer-
ous lesions [16], the hypothetical use of diagnostic nanocarriers
for early detection of some cancer types is an exciting possibility
that demands to be explored. Furthermore, senescence-
activatable NPs could potentially be employed as theranostic
tools, aimed at the simultaneous detection and eradication of se-
nescent lesions associated with human chronic disorders or natu-
ral ageing.
1.3. Future perspectives: challenges and limitations
A relevant advantage of targeted encapsulation methods (either
diagnostic or therapeutic) is the protection of healthy tissues from
the exposure to the administered compounds. Accordingly, we
found in mice that gal-encapsulation of drugs and senolytics
reduced the associated off-target effects of the free compounds,
as it is shown for doxorubicin cardiotoxicity and for navitoclax-
induced thrombocytopenia [10]. The development of nanotechnol-
ogies to target senescent cells is however still in its infancy, and it is
the subject of safety concerns and long-term risks. Translation of
preclinical studies into early phase clinical trials will imply a better
and complete understanding of the cellular uptake and intracel-
lular trafﬁcking of NPs, biocompatibility and biodistribution prop-
erties, pharmacokinetics/pharmacodynamics (PK/PD) analyses,
and routes of administration/elimination of the core materials in
animal models.
In the particular case of mesoporous silica nanoparticles, and
other silica formulations of various physicochemical properties,
there is solid evidence that NPs accumulate mainly in the
lungs of healthy mice at early post-tail vein injection times [17].
NPs are, however, rapidly cleared from the lungs and partially
sequestered by the mononuclear phagocytic system (MPS,
including liver, spleen and lymph nodes). This is in part due to
discontinuous gaps in the endothelium lining the sinusoidal walls
of these organs, allowing a passive entrapment of foreign nanopar-
ticles. In addition, resident macrophages can identify nanoparticles
as foreign substances that need to be engulfed, degraded and elim-
inated. This scenario applies not only to silica nanoparticles but also
to multiple NPs types, which weights down potential translational
applications. In this regard, we found that a substantial number of
cells targeted by GalNPs were macrophages, although these levels
were reduced in ﬁbrotic lungs when compared to healthy lungs,
presumably because of the presence of senescent ﬁbroblasts and
alveolar epithelial cells competing for nanoparticles [10]. The pos-
sibility that macrophages with a high SAbgal activity [18] can acti-
vate GalNPs encapsulating drugs is yet to be tested in our
experimental settings. It is however worth mentioning that no ev-
idence of hepatic or renal damage was gathered following daily
treatments of GalNPs encapsulating doxorubicin for more than
two weeks, as evaluated by serum markers and histology. The
absence of altered blood parameters suggests that doxorubicin is
not signiﬁcantly released when GalNPs are taken up by non-
senescent cells, being eventually removed by exocytosis [19]. Excre-
tion of silica NPs or their degraded products occurs principally
through the urine by renal clearance and, to a lesser extent, in
faeces, with a peak at 24 hours post-administration for both routes
[17].
A promising clinical application of NPs targeting senescent cells
is their use in combination with standard (senescence-inducing)
chemotherapies [10] (Fig. 2). This strategy may beneﬁt from the
extravasation of NPs from the tumour blood vessels into the
tumour microenvironment through gaps between adjacent endo-
thelial cells, an effect known as enhanced permeability and reten-
tion (EPR), a product of leaky tumour vasculature and poor
lymphatic drainage [20,21]. This potential effect in humans, howev-
er, has been hardly explored, and most of the available data have
been obtained in preclinical animal models. In this regard, elucida-
tion of whether impaired angiogenesis and endothelial dysfunction
in the elderly may reduce the effectiveness of interventions based
on systemic administration of NPs is yet to be conducted. For the
time being, PK data of nanomaterials on naturally-aged mouse
models and vascular disorders are currently limited. Similarly, a po-
tential pitfall in some age-related disorders accumulating senes-
cent cells is the possibility that the senescent secretome,
including inﬂammatory cytokines, growth factors and tissue
remodelling proteases, affects the blood supply to the damaged tis-
sue, thereby precluding targeting of nanoparticles and drug deliv-
ery. Although this possibility cannot be ruled out in some
experimental settings, depending on the particular nanotech-
nology, organ, and disease model, similar levels of GalNPs encapsu-
lating a ﬂuorescent compound were measured in healthy and
bleomycin-treated mouse lungs enriched in senescent cells, indi-
cating that the diffusion of NPs was not altered [10]. Intracellular
release of the ﬂuorophore preferentially occurred in ﬁbrotic lungs,
remarkably. It is important to recall that intravenous administra-
tion of GalNPs in mice results in a preferential lung accumulation
due to the anatomic distribution of the blood ﬂow. It seems likely
that organs with a relevant blood supply, such as the heart, liver,
or kidneys, can be targeted by these or similar nanocarriers. In
the particular case of the brain, there are some reported examples
of polymeric NPs capable to deliver drugs, but this has posed a
big challenge due to the intrinsic limitations associated with the
blood brain barrier (BBB), making uncertain the potential use of
mesoporous silica nanoparticles [22]. An interesting alternative to
systemic injection of GalNPs would be exploring direct routes of
administration, such as a transdermal drug delivery system if the
target is the skin, or oral uptake when the target is the digestive
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system. Addressing the utility of GalNPs to target other organs and
tissues containing senescent lesions, especially for those having a
reduced blood circulation, will require further work.
Only a few (non-targeted) NPs formulations enjoy at present
approval for clinical use (e.g. Abraxane or Doxil) [23], mainly
because of the limited information available in the use of nanode-
vices in in vivo and of safety concerns, which underlies the impor-
tance of a better understanding and controlled delivery of NPs in
live organisms. Physicochemical properties of NPs affect the bio-
logical processes involved in the delivery to target tissues,
including interactions with serum proteins (such as opsonins),
blood circulation, biodistribution, competition with other organs
and cells (i.e. MPS, macrophages, or renal clearance), extravasa-
tion, and speciﬁc cell targeting. Increasing the selectivity of nano-
carriers for senescent cells is crucial to improve delivery. In this
respect, it is imperative to carry out some fundamental research
on the characterisation of more precise markers of senescent cells.
As an example, the identiﬁcation of senescence-speciﬁc mem-
brane markers would facilitate the functionalisation of nanodevi-
ces with speciﬁc antibodies to target senescent cells, such as the
recently reported surface targetable protein DPP4, expressed pref-
erentially in senescent but not proliferating human diploid ﬁbro-
blasts [24]. Despite some other membrane-associated proteins in
the surfacesome of senescent cells being found (such as DEP1 or
BMG2), a universal marker of cellular senescence is still lacking
[25]. Senescent cells accumulate in a broad number of age-
related disorders and during ageing and therefore they appear to
escape from immunosurveillance and clearance. This could be
due to the absence of distinct antigenic determinants in their
membranes when compared to normal (healthy) cells, but also
to the implementation of detrimental secretory programmes
causing immunosuppression, or to a deﬁcient inﬁltration of cells
of the immune system in the “remodelled” microenvironment of
senescent cells. Of note, although yet to be tested in vivo, the
in vitro validation of CD9-Lac/CaCO3 NPs targeting a cell surface
glycoprotein receptor overexpressed in senescent cells [11] is a
promising ﬁrst step.
2. Conclusions
Altogether, nanotechnologies constitute an innovative strategy
to speciﬁcally target senescent cells for potential andmultiple diag-
nostic and therapeutic interventions. Vehicles designed for a selec-
tive cargo delivery could be used for detection, longitudinal
monitoring, elimination and manipulation of senescent cells.
Further studies with second generation senescence-speciﬁc nano-
carriers and a better comprehension of their dynamic behaviour
in preclinical models of senescence-associated disorders will be
fundamental in providing opportunities for successful translational
applications.
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